http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#Head http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#provenance http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#pubinfo http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion http://purl.obolibrary.org/obo/DOID_8689 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8689 http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01156 http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association http://www.w3.org/2000/01/rdf-schema#label "Seizure disorder. ( 4 5.3 Current or prior diagnosis of bulimia or anorexia nervosa ( 4 5.3 Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. ( 4 5.3 Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with bupropion hydrochloride extended-release tablets (XL) or within 14 days of stopping treatment with bupropion hydrochloride extended-release tablets (XL). Do not use bupropion hydrochloride extended-release tablets (XL) within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start bupropion hydrochloride extended-release tablets (XL) in a patient who is being treated with linezolid or intravenous methylene blue. ( 4 7.6 Known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL) ( 4 5.8 Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder. Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder. Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL) [ see Warnings and Precautions (5.3) Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [ see Warnings and Precautions (5.3) Drug Interactions (7.3) The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [ see Dosage and Administration (2.9) Warnings and Precautions (5.4) Drug Interactions (7.6) Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [ see Warnings and Precautions (5.8)" http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB01156 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#provenance http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#pubinfo http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#sig http://purl.org/nanopub/x/hasSignature NY+eQcEAzcAHy6mXGLxq0ZWUy+DbAtkjO8jdVG3WPNkhJGjX7+GlbRba4gCdFma1LSMEMY9QzUXlN/vTG0L+VhxA4c9Ik8FityvKkMcfy8hOfjVZGfvYUdj6lnf4OD90Ila45r1EDAshg3p7oaSomsSGVfRhFNhpXAFBbGabUt8= http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 http://purl.org/dc/terms/created 2021-08-23T12:42:57.559+02:00 http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA54uwyajS6dCS0hjZgsPoqFOUWR7TZbTn0DLahOeDiq0 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY